carisoprodol (soma) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache. Carisoprodol might be mixtured with Aspirin and Codeine Phosphate. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market in Norway and other EU countries in 2008.   NCATS

Chemistry

  • SMILES: CCCC(C)(COC(N)=O)COC(=O)NC(C)C
  • InChIKey: OFZCIYFFPZCNJE-UHFFFAOYSA-N
  • Mol. Mass: 260.33
  • ALogP: 2.02
  • ChEMBL Molecules:
    carisoprodol  
    teclozan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0475 - $6.8008
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester | (+-)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate | 2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate | 2-methyl-2-propyltrimethylene carbamate isopropylcarbamate | carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester | carisoma | carisoprodate | carisoprodol | carisoprodolum | isobamate | isomeprobamate | isopropylmeprobamate | isopropyl meprobamate | n-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate | rela | (rs)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate | soma | someprobamate

Organizations (32)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (29)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (3)


 

Muscular Diseases (approved 1959)

Pain

Spasm

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Low Back Pain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue